fool.com · 30 jun

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

seekingalpha.com · 22 jun

Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet

Summit Therapeutics is a highly volatile, single-asset company with a binary outcome. SMMT exhibits unusually concentrated ownership and heightened short interest, creating conditions for a short squeeze to take place. Recent pullbacks, driven by mixed market receptions to events do not fundamentally alter the investment narratives, present investors with an attractive entry point ahead of key catalysts.

businesswire.com · 9 jun

Summit Therapeutics Announces Proposed Public Offering of Common Stock

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Summit. In addition, Summit intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares of its common stock at the public offering price, less underwriting discounts and c.

seekingalpha.com · 8 jun

Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Summit Therapeutics Inc. (SMMT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

247wallst.com · 7 jun

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

After years of lagging the market, healthcare may be taking on a new role in investor portfolios.

wsj.com · 6 jun

The Era of the One-Size-Fits-All Cancer Drug Is Ending

Investors have bet new drugs can topple Merck's Keytruda, but the evidence so far points to something smaller.

businesswire.com · 4 jun

Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM ET, providing a corporate overview and update on recent progress, including the development of its innovative investigational bispecific antibody, ivonescimab. The presentatio.

zacks.com · 4 jun

All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy

Summit Therapeutics (SMMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.